Value Proposition
Why Raer?
Our approach
We use whole-body, robotics-based screening methods and mammalian validation. This provides a sensible path to clinics.
Unique Platform
Using Drosophila, mouse, and human models, Raer’s platform is rapid, cost-effective, and scalable. These methods are experienced in experimental clinical trials (Bangi et al, 2019, 2021).
Elite Team
Raer is led by people who are world-respected for innovative therapeutic solutions. We have complementary science/business skills, startup experience, and long-term working relationships.
Deliverables
First, in the short term, Raer will deliver five initial projects that will translate to treatment leads for five rare genetic disorders. In the medium term, we will tackle leads for up to 30 diseases. Our long-term plan will develop a protectable, novel COM.